BIOMARKERS IN PRECISION ONCOLOGY: CURRENT STATUS AND FUTURE DIRECTIONS

Abstract

Precision oncology has emerged as a critical component in the evolution of cancer treatment, offering personalized therapeutic strategies based on individual molecular profiles. The identification of reliable biomarkers is central to the success of precision oncology, aiding in early detection, prognostication, treatment selection, and monitoring of therapeutic responses. This article reviews the current status of biomarkers used in precision oncology, exploring their role in advancing cancer treatment. Furthermore, we discuss challenges such as biomarker validation, the need for personalized diagnostics, and the emerging trends in the field, including liquid biopsy and next-generation sequencing. The article concludes with future directions and the potential for novel biomarkers to further revolutionize cancer care, highlighting their integration into clinical practice and the importance of global research efforts.